NCT07196501View on ClinicalTrials.gov

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

PHASE3RecruitingINTERVENTIONAL
Enrollment

550

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Major Depressive Disorder
Interventions
DRUG

NBI-1065845

Oral tablet

DRUG

Placebo

Oral tablet

Trial Locations (4)

32901

RECRUITING

Neurocrine Clinical Site, Melbourne

33014

RECRUITING

Neurocrine Clinical Site, Miami Gardens

63368

RECRUITING

Neurocrine Clinical Site, O'Fallon

77546

RECRUITING

Neurocrine Clinical Site, Friendswood

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY